Ascletis Pharma Stock Buy Hold or Sell Recommendation
| ASCLF Stock | USD 0.24 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Ascletis Pharma is 'Strong Sell'. Macroaxis provides Ascletis Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ASCLF positions.
Check out Ascletis Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Ascletis and provide practical buy, sell, or hold advice based on investors' constraints. Ascletis Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Ascletis |
Execute Ascletis Pharma Buy or Sell Advice
The Ascletis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Ascletis Pharma. Macroaxis does not own or have any residual interests in Ascletis Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ascletis Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Ascletis Pharma Trading Alerts and Improvement Suggestions
| Ascletis Pharma is way too risky over 90 days horizon | |
| Ascletis Pharma has some characteristics of a very speculative penny stock | |
| Ascletis Pharma appears to be risky and price may revert if volatility continues | |
| Ascletis Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 76.88 M. Net Loss for the year was (199.02 M) with profit before overhead, payroll, taxes, and interest of 39.17 M. | |
| Ascletis Pharma has accumulated about 2.5 B in cash with (146.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by company insiders |
Ascletis Pharma current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ascletis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ascletis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Ascletis Pharma Returns Distribution Density
The distribution of Ascletis Pharma's historical returns is an attempt to chart the uncertainty of Ascletis Pharma's future price movements. The chart of the probability distribution of Ascletis Pharma daily returns describes the distribution of returns around its average expected value. We use Ascletis Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ascletis Pharma returns is essential to provide solid investment advice for Ascletis Pharma.
| Mean Return | 0.73 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 5.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ascletis Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ascletis Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ascletis Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ascletis Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ascletis pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.75 | |
β | Beta against Dow Jones | -0.36 | |
σ | Overall volatility | 5.30 | |
Ir | Information ratio | 0.12 |
Ascletis Pharma Volatility Alert
Ascletis Pharma exhibits very low volatility with skewness of 4.35 and kurtosis of 27.27. Ascletis Pharma is a potential penny stock. Although Ascletis Pharma may be in fact a good instrument to invest, many penny pink sheets are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Ascletis Pharma. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Ascletis instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Ascletis Pharma Fundamentals Vs Peers
Comparing Ascletis Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ascletis Pharma's direct or indirect competition across all of the common fundamentals between Ascletis Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ascletis Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Ascletis Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Ascletis Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ascletis Pharma to competition |
| Fundamentals | Ascletis Pharma | Peer Average |
| Return On Equity | -0.0632 | -0.31 |
| Return On Asset | -0.053 | -0.14 |
| Profit Margin | (2.24) % | (1.27) % |
| Operating Margin | (3.11) % | (5.51) % |
| Current Valuation | 116.15 M | 16.62 B |
| Shares Outstanding | 1.09 B | 571.82 M |
| Shares Owned By Insiders | 67.02 % | 10.09 % |
| Shares Owned By Institutions | 1.94 % | 39.21 % |
| Price To Book | 1.58 X | 9.51 X |
| Price To Sales | 7.61 X | 11.42 X |
| Revenue | 76.88 M | 9.43 B |
| Gross Profit | 39.17 M | 27.38 B |
| EBITDA | (169.35 M) | 3.9 B |
| Net Income | (199.02 M) | 570.98 M |
| Cash And Equivalents | 2.5 B | 2.7 B |
| Cash Per Share | 2.28 X | 5.01 X |
| Total Debt | 2.75 M | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 28.93 X | 2.16 X |
| Book Value Per Share | 2.50 X | 1.93 K |
| Cash Flow From Operations | (146.93 M) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Number Of Employees | 315 | 18.84 K |
| Beta | 0.81 | -0.15 |
| Market Capitalization | 672.93 M | 19.03 B |
| Total Asset | 2.83 B | 29.47 B |
| Net Asset | 2.83 B |
Ascletis Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ascletis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Ascletis Pharma Buy or Sell Advice
When is the right time to buy or sell Ascletis Pharma? Buying financial instruments such as Ascletis Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ascletis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Funds Thematic Idea Now
Precious Metals Funds
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.